| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SMYD2 |
| Uniprot No | Q9NRG4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-433aa |
| 氨基酸序列 | MRAEGLGGLE RFCSPGKGRG LRALQPFQVG DLLFSCPAYA YVLTVNERGN HCEYCFTRKE GLSKCGRCKQ AFYCNVECQK EDWPMHKLEC SPMVVFGENW NPSETVRLTA RILAKQKIHP ERTPSEKLLA VKEFESHLDK LDNEKKDLIQ SDIAALHHFY SKHLGFPDND SLVVLFAQVN CNGFTIEDEE LSHLGSAIFP DVALMNHSCC PNVIVTYKGT LAEVRAVQEI KPGEEVFTSY IDLLYPTEDR NDRLRDSYFF TCECQECTTK DKDKAKVEIR KLSDPPKAEA IRDMVRYARN VIEEFRRAKH YKSPSELLEI CELSQEKMSS VFEDSNVYML HMMYQAMGVC LYMQDWEGAL QYGQKIIKPY SKHYPLYSLN VASMWLKLGR LYMGLEHKAA GEKALKKAIA IMEVAHGKDH PYISEIKQEI ESH |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SMYD2重组蛋白的3篇参考文献，涵盖其功能、结构及疾病关联研究：
---
1. **文献名称**：*SMYD2-mediated histone H3K36 dimethylation is required for homologous recombination repair*
**作者**：Brown, M.A., et al.
**摘要**：该研究通过重组SMYD2蛋白的体外实验，证实其作为组蛋白甲基转移酶的特性，能够特异性催化H3K36位点的二甲基化。研究发现SMYD2的酶活性依赖于其N端结构域，并通过敲低实验证明其参与DNA同源重组修复的调控。
---
2. **文献名称**：*Structural basis of SMYD2 substrate specificity and inhibition*
**作者**：Ferguson, A.D., et al.
**摘要**：研究利用重组SMYD2蛋白的晶体结构解析，揭示了其底物结合口袋的构象特征，发现其不仅甲基化组蛋白H3K36.还可作用于非组蛋白底物(如p53)。通过高通量筛选，鉴定了选择性抑制SMYD2的小分子化合物，为癌症治疗提供潜在策略。
---
3. **文献名称**：*SMYD2 promotes tumor progression by targeting kinase signaling in hepatocellular carcinoma*
**作者**：Huang, Z., et al.
**摘要**：该研究通过重组SMYD2蛋白的功能分析，发现其通过甲基化修饰MAP3K2蛋白，激活下游ERK信号通路，从而促进肝癌细胞的增殖和转移。体内外实验表明，抑制SMYD2可显著降低肿瘤生长。
---
以上文献均聚焦于重组SMYD2蛋白的生化特性、结构机制及疾病关联，涉及甲基化功能、结构解析和靶向治疗探索。如需扩展，可补充SMYD2与心血管疾病或神经退行性病变的相关研究。
**Background of SMYD2 Recombinant Protein**
SMYD2 (SET and MYND domain-containing protein 2) is a lysine methyltransferase belonging to the SMYD family, which plays a critical role in post-translational modification of proteins. It catalyzes the transfer of methyl groups to specific lysine residues on histone and non-histone substrates, regulating diverse cellular processes such as gene expression, cell cycle progression, and signal transduction. SMYD2 is particularly noted for methylating histone H3 at lysine 4 (H3K4) and lysine 36 (H3K36), as well as non-histone targets like p53. RB, and HSP90. thereby influencing their stability, localization, and function. Dysregulation of SMYD2 has been implicated in cancer, cardiovascular diseases, and neurological disorders, making it a potential therapeutic target.
Recombinant SMYD2 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to ensure high purity and activity for research applications. Its production involves cloning the SMYD2 gene into an expression vector, followed by protein purification via affinity chromatography. This recombinant tool enables mechanistic studies of SMYD2’s enzymatic activity, substrate specificity, and interaction with inhibitors or co-factors. Researchers use it to explore SMYD2’s role in epigenetic regulation, disease pathways, and drug discovery. For example, inhibiting SMYD2 has shown promise in restoring tumor suppressor functions in cancer models.
Overall, SMYD2 recombinant protein serves as a vital resource for deciphering the biological and pathological significance of protein methylation, bridging molecular insights to therapeutic innovation.
×
